Dana-Farber Cancer Scientists to Use HistoRx's Biomarker Profiling Tech | GenomeWeb
NEW YORK (GenomeWeb News) – Researchers at the Dana-Farber/Harvard Cancer Center will use HistoRx’s Aqua biomarker profiling technology in cancer studies and cancer treatment research, the company said Thursday.
More than 900 researchers at DF/HCC will use the company’s PM-2000 tissue analysis tool, which was purchased by Brigham and Women’s Hospital for its pathology core facility in 2005.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.